Milestone Pharmaceuticals

OverviewSuggest Edit

Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of paroxysmal supraventricular tachycardia (PSVT).

The Company employs a lean and cost efficient model which has the effect of minimizing overhead and focusing spending on the programs. It has assembled a core seasoned management team with expertise in cardiovascular clinical drug development, regulatory affairs, chemistry and manufacturing, and commercial preparedness which is guided by world-class key opinion leaders (KOLs) and advisors.

TypePublic
Founded2005
HQMontréal, CA
Websitemilestonepharma.com

Latest Updates

Employees (est.) (Dec 2019)30
Share Price (Nov 2021)$6(+10%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Milestone Pharmaceuticals

Joseph Oliveto

Joseph Oliveto

President & CEO
Philippe Douville

Philippe Douville

Founder and Strategic Advisor
Robert J. Wills

Robert J. Wills

Chairman of the Board
Francis Plat

Francis Plat

Chief Medical Officer
Lisa M. Giles

Lisa M. Giles

Independent Non-Executive Director
Lorenz Muller

Lorenz Muller

Chief Commercial Officer
Show more

Milestone Pharmaceuticals Office Locations

Milestone Pharmaceuticals has offices in Montréal and Charlotte
Montréal, CA (HQ)
420 1111 Boulevard Dr.-Frederik-Philips
Charlotte, NC, US
7422 Carmel Executive Park Dr #300
Show all (2)

Milestone Pharmaceuticals Financials and Metrics

Milestone Pharmaceuticals Revenue

USD

Net income (FY, 2020)

(50.0m)

EBIT (FY, 2020)

(50.7m)

Market capitalization (12-Nov-2021)

167.1m

Closing stock price (12-Nov-2021)

6.0

Cash (31-Dec-2020)

72.3m

EV

95.8m
Milestone Pharmaceuticals's current market capitalization is $167.1 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

1.5m3.1m7.0m10.3m

R&D expense

5.6m16.8m42.0m34.5m

Operating expense total

8.3m23.8m49.0m44.8m

EBIT

(8.3m)(23.8m)(57.9m)(50.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

979.0k1.6m2.1m2.7m3.0m

R&D expense

7.8m10.5m9.5m11.9m8.6m

Operating expense total

8.7m12.2m11.6m14.6m11.6m

EBIT

(10.9m)(14.3m)(13.7m)(16.8m)(13.1m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

10.9m85.9m119.8m72.3m

Accounts Receivable

258.0k223.0k

Prepaid Expenses

100.0k1.4m1.8m5.4m

Current Assets

27.6m88.1m122.5m148.7m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

71.2m110.8m106.5m101.8m53.4m

Accounts Receivable

265.0k338.0k497.0k259.0k318.0k

Prepaid Expenses

5.5m5.0m3.5m1.6m6.1m

Current Assets

77.3m151.6m141.0m104.3m92.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(8.1m)(23.2m)(55.2m)(50.0m)

Depreciation and Amortization

8.0k10.0k38.0k97.0k

Accounts Payable

(222.0k)2.9m3.5m(2.1m)

Cash From Operating Activities

(8.1m)(21.0m)(51.2m)(50.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(10.5m)(24.1m)(36.9m)(16.3m)(29.3m)

Depreciation and Amortization

3.0k5.0k14.0k24.0k49.0k

Accounts Payable

(571.0k)1.1m4.0m(2.8m)(3.2m)

Cash From Operating Activities

(14.7m)(26.3m)(34.5m)(18.1m)(34.6m)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Milestone Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Milestone Pharmaceuticals Online and Social Media Presence

Embed Graph

Milestone Pharmaceuticals News and Updates

Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update

MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended...

Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and...

Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief...

Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT

– RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT – – RAPID investigates efficacy of second dose of etripamil for patients with persistent PSVT – – RAPID results expected late 2021/early 2022 – MONTREAL...

Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update

MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended...

Thinking about buying stock in Arbutus Biopharma, Polarityte Inc, Milestone Pharmaceuticals, Vonage, or BioNano Genomics?

NEW YORK, July 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, PTE, MIST, VG, and BNGO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Milestone Pharmaceuticals Blogs

Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT

Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT Content Import Mon, 11/15/2021 - 07:05 Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT …

Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update Content Import Wed, 08/11/2021 - 16:19 Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update August…

Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia in the United States

This study utilized claims data from both Medicare and private insurers to estimate the treated prevalence and incidence of PSVT in the U.S. over a… The post Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia in the United States appeared first on Milestone Pharma.

Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update Content Import Mon, 05/17/2021 - 07:03 Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Upda…

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 Content Import Mon, 05/17/2021 - 07:03 Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 May 17, 2021 This release is a b…
Show more

Milestone Pharmaceuticals Frequently Asked Questions

  • When was Milestone Pharmaceuticals founded?

    Milestone Pharmaceuticals was founded in 2005.

  • Who are Milestone Pharmaceuticals key executives?

    Milestone Pharmaceuticals's key executives are Joseph Oliveto, Philippe Douville and Robert J. Wills.

  • How many employees does Milestone Pharmaceuticals have?

    Milestone Pharmaceuticals has 30 employees.

  • Who are Milestone Pharmaceuticals competitors?

    Competitors of Milestone Pharmaceuticals include Alembic Pharmaceuticals, EMS Pharma and YiChang HEC ChangJiang Pharmaceutical.

  • Where is Milestone Pharmaceuticals headquarters?

    Milestone Pharmaceuticals headquarters is located at 420 1111 Boulevard Dr.-Frederik-Philips, Montréal.

  • Where are Milestone Pharmaceuticals offices?

    Milestone Pharmaceuticals has offices in Montréal and Charlotte.

  • How many offices does Milestone Pharmaceuticals have?

    Milestone Pharmaceuticals has 2 offices.